| Car Trips Lead to Couple Clashes Spats over directions, arguments over who gets to drive -- even the speed of the windshield wiper -- can push some relationships to the brink. Here's how some cope, from finger puppets to the OnStar operator. online.wsj.com |
Don't Sleep Through Cephalon's Growth Ockham Research submits: Cephalon (CEPH) is a biopharmaceutical company that we have highlighted in the past, and it reported another outstanding quarter after the close on Tuesday. The company’s most successful drug is Provigil, which is used to treat some sleep disorders, but for some reason we think the market has been lulled into sleepiness when it comes to this growth story. The company reported revenue of $712.4 million, or 32% growth over the second quarter last year. Adjusted for income per share came in at $2.20 per share, 41% better than a year ago and $.43 cents better than Wall Street expected (that is after 9 analysts upped their targets in just the last month). The company experienced growth in all different categories of drugs with oncology drug Treanda being a standout from the bunch.Complete Story » seekingalpha.com |
How Technology Tries Our Eyes Many people who complain to an eye doctor about headaches and neck pain aren't being adequately tested for vision in the area most commonly used by computer users. online.wsj.com |
Bigger Doors Open for Aveo as Merck Deal Closes EP Vantage submits:It is normally taken as bad news when a big pharma partner hands back rights to a drug – unless you are Aveo Pharmaceuticals (AVEO). Shares in the Massachusetts company have surged 43% since Merck & Co (MRK) terminated a deal over lung cancer drug AV-299 last week, reaching a record high of $15 on Thursday. Aveo listed on Nasdaq in March and these gains mean the stock is the only US biotech IPO of 2010 to be trading above its offer price; a notable achievement. Investors appear convinced that Merck's decision does not reflect badly on AV-299 and are only looking at the potential for lucrative new deals to be struck. This certainly looks possible; the company now owns broad rights to two promising anti-cancer products, on which important phase II and III data are due next year, and has enough cash to last until then. With oncology remaining a hot area for deals and Aveo unencumbered by partners, the company is emerging as one to watch.Complete Story » seekingalpha.com |
When Achy Legs Are a Warning Between eight and 12 million Americans have peripheral artery disease, a potentially fatal blockage of large arteries in the legs. But awareness is low among doctors and patients, complicating treatment. online.wsj.com |